Skip to main content
Tags: bristol myers | pfizer | eliquis | patients

Bristol Myers, Pfizer to Sell Blood Thinner Eliquis Directly to Patients

Thursday, 17 July 2025 07:59 AM EDT

Drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program. Eligible patients will be able to buy the drug directly through the Eliquis 360 Support program from September 8 at a rate that is more than 40% lower than the current list price.

"Eliquis is the nation's number one prescribed oral anticoagulant that provides important benefits to patients and the healthcare system," said Bristol Myers CEO Christopher Boerner.

"This program passes more savings directly to patients."

Since its launch, Eliquis has been prescribed to over 15 million Americans and in 2024 it generated about $11.4 billion in global revenue. 

© 2025 Thomson/Reuters. All rights reserved.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.

Newsfront
Drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program. Eligible patients will be able to buy the drug directly through the Eliquis 360...
bristol myers, pfizer, eliquis, patients
117
2025-59-17
Thursday, 17 July 2025 07:59 AM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 

Interest-Based Advertising | Do not sell or share my personal information

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© 2025 Newsmax Media, Inc.
All Rights Reserved
Download the Newsmax App
NEWSMAX.COM
America's News Page
© 2025 Newsmax Media, Inc.
All Rights Reserved